Immunic Inc Total Liabilities
Immunic Inc total liabilities. Based on the latest financial reports, Immunic Inc (IMUX) has total liabilities worth $30.73 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IMUX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Immunic Inc (2011–2025)
Total liabilities of Immunic Inc from 2011 to 2025. This chart illustrates how Immunic Inc's total liabilities have evolved over time, based on quarterly financial data.
Immunic Inc Competitors by Total Liabilities
The table below lists competitors of Immunic Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Merkur PrivatBank KgaA
XETRA:MBK
|
Germany | €4.11 Billion |
|
Falco Resources Ltd
V:FPC
|
Canada | CA$112.79 Million |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
USA | $222.87 Million |
|
Marks and Spencer Group PLC
LSE:MKS
|
UK | GBX6.89 Billion |
|
FSA Group Ltd
AU:FSA
|
Australia | AU$949.95 Million |
|
Syrah Resources Ltd
AU:SYR
|
Australia | AU$385.70 Million |
|
Southern Acids (M) Bhd
KLSE:5134
|
Malaysia | RM123.71 Million |
|
Alan Allman Associates SA
PA:AAA
|
France | €268.96 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Immunic Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IMUX current and non-current assets.
Liquidity & Leverage Metrics
Immunic Inc Total Liabilities Ratios Explained
Immunic Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunic Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunic Inc (2011–2025)
The table below shows the annual total liabilities of Immunic Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $30.73 Million | +36.93% |
| 2024-12-31 | $22.44 Million | -11.55% |
| 2023-12-31 | $25.37 Million | +80.31% |
| 2022-12-31 | $14.07 Million | +17.39% |
| 2021-12-31 | $11.98 Million | +32.05% |
| 2020-12-31 | $9.08 Million | +19.55% |
| 2019-12-31 | $7.59 Million | +197.61% |
| 2018-12-31 | $2.55 Million | -75.33% |
| 2017-12-31 | $10.34 Million | +85.30% |
| 2016-12-31 | $5.58 Million | -17.41% |
| 2015-12-31 | $6.76 Million | -35.77% |
| 2014-12-31 | $10.52 Million | +103.58% |
| 2013-12-31 | $5.17 Million | -81.52% |
| 2012-12-31 | $27.96 Million | -50.80% |
| 2011-12-31 | $56.84 Million | -- |
About Immunic Inc
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative… Read more